LeMaitre Vascular Inc (NASDAQ:LMAT) announced a quarterly dividend on Friday, July 27th, Wall Street Journal reports. Investors of record on Wednesday, August 22nd will be paid a dividend of 0.07 per share by the medical instruments supplier on Thursday, September 6th. This represents a $0.28 annualized dividend and a yield of 0.75%. The ex-dividend date of this dividend is Tuesday, August 21st.

LeMaitre Vascular has increased its dividend by an average of 16.3% annually over the last three years and has raised its dividend annually for the last 2 consecutive years. LeMaitre Vascular has a dividend payout ratio of 26.2% indicating that its dividend is sufficiently covered by earnings. Research analysts expect LeMaitre Vascular to earn $1.00 per share next year, which means the company should continue to be able to cover its $0.28 annual dividend with an expected future payout ratio of 28.0%.

Shares of LMAT stock opened at $37.09 on Monday. LeMaitre Vascular has a 12-month low of $28.23 and a 12-month high of $41.28. The company has a market capitalization of $706.45 million, a P/E ratio of 43.13, a P/E/G ratio of 2.28 and a beta of 0.59.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, July 26th. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.42 by ($0.21). LeMaitre Vascular had a return on equity of 19.49% and a net margin of 21.09%. The company had revenue of $27.02 million during the quarter, compared to analysts’ expectations of $27.09 million. During the same quarter in the prior year, the business posted $0.23 EPS. The company’s revenue for the quarter was up 4.9% compared to the same quarter last year. analysts expect that LeMaitre Vascular will post 1.07 EPS for the current fiscal year.

In other LeMaitre Vascular news, Director David B. Roberts sold 21,005 shares of the stock in a transaction that occurred on Thursday, August 2nd. The shares were sold at an average price of $35.72, for a total value of $750,298.60. Following the transaction, the director now directly owns 5,373 shares in the company, valued at $191,923.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO George W. Lemaitre sold 30,000 shares of the stock in a transaction that occurred on Wednesday, May 23rd. The stock was sold at an average price of $33.05, for a total transaction of $991,500.00. Following the completion of the transaction, the chief executive officer now owns 3,157,009 shares in the company, valued at $104,339,147.45. The disclosure for this sale can be found here. Insiders sold 189,379 shares of company stock worth $6,726,178 over the last quarter. Insiders own 20.30% of the company’s stock.

Several equities research analysts recently issued reports on the stock. Canaccord Genuity raised their target price on shares of LeMaitre Vascular from $31.00 to $35.00 and gave the stock a “hold” rating in a report on Monday, July 9th. BidaskClub cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, June 22nd. ValuEngine cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Monday, July 30th. Zacks Investment Research cut shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Wednesday, August 1st. Finally, Stifel Nicolaus cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating and dropped their target price for the stock from $40.00 to $34.00 in a report on Thursday, April 26th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. LeMaitre Vascular has an average rating of “Hold” and an average target price of $38.00.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Recommended Story: Marijuana Stocks Future Looks Bright

Dividend History for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.